New drug combo aims to shrink rare gut tumors

NCT ID NCT04086485

First seen Oct 31, 2025

Summary

This study tests whether combining two drugs, Lutathera and Olaparib, can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive Lutathera by IV every 8 weeks and take Olaparib pills twice daily. The goal is to find a safe dose and see if the tumors respond.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

Conditions

The condition(s) this trial relates to.

carcinoid tumor neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.